Phillips-Medisize LLC (Phillips-Medisize), a subsidiary of Molex LLC, is a provider of innovation, development and manufacturing solutions to the drug delivery, diagnostics, med tech, defense, automotive and consumer markets. The company offers design and development, manufacturing development, commercial manufacturing, quality and regulatory services.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Phillips-Medisize focuses on innovating capabilities in the design, development, and manufacturing of drug-delivery products. The company emphasizes product innovation to achieve rapid commercialization. Phillips-Medisize develops therapy-specific features, functions, and designs for each new application, ensuring individual patient needs and the unique characteristics of each drug. Phillips-Medisize integrates product development and commercial manufacturing to reduce risk and accelerate time to market, combining user-centric design with an emphasis on manufacturing.The R&D units of the company include seven innovation centers and 23 production facilities across the US, Europe, and Asia. These units are responsible for managing the company's R&D activities, ensuring collaboration across continents, and delivering services where customers are located. The units focus on new product introduction, tool-building, and maintaining global standards for injection molding, automation, and validation.The company operates in seven R&D centers which has been involved in the development of various products, including autoinjectors, ocular drug delivery systems, in vitro diagnostic devices, pen injectors, inhalation devices, and electro-mechanical drug delivery devices. The company focuses on designing and innovating physical, digital, and service products, developing them through an agile, controlled process, and integrating product and manufacturing development to deliver safe and effective products.